DeutschNewstral
Article
jdsupra.com on 2015-09-04 02:11
PTO Has Broad Discretion in Considering Extraordinary Situations for Patent Term Adjustment - Daiichi Sankyo Co. Ltd. v. Michelle K. Lee
Related news
- Apotex Inc. v. Daiichi Sankyo, Inc.jdsupra.com
- Apotex, Inc. v. Daiichi Sankyo, Inc.jdsupra.com
- Daiichi Sankyo Co. v. Lee (Fed. Cir. 2015)jdsupra.com
- Declaratory Judgment of Non-Infringement of a Disclaimed Patent Warranted in Hatch-Waxman - Apotex Inc. v. Daiichi Sankyo, Inc.jdsupra.com
- LVenous Thromboembolism Product Market SWOT Analysis, Key Indicators, Forecast 2028: Bristol-Myers Squibb Company, Sanofi S.A., Pfizer Inc., Daiichi Sankyo Co. Ltd.liverpoolstudentmedia.com
Georgia gets $416,000 from Daiichi Sankyo settlementbizjournals.com- PTAB Discretion to Institute Trials: PTO seeks comments whether to propose rulesjdsupra.com
- Supernus: Federal Circuit Provides Clarity on USPTO Discretion on Patent-Term Adjustment Calculationsjdsupra.com
- Federal Circuit Sides with PTO on Applicant Delay in Patent Term Adjustmentjdsupra.com
- PTO Proposes Standardization of the Patent Term Adjustment Statement Regarding Information Disclosure Statementsjdsupra.com
U.S. fines drug maker Daiichi Sankyo $39 million over kickbacksThe Japan Times
FDA Approves New Oral Anticoagulant From Daiichi SankyoForbes
AstraZeneca, Daiichi Sankyo to Sell Constipation Drug in U.S.wsj.com
Maryland to share in settlement with drug company Daiichi Sankyothedailyrecord.com
AstraZeneca agrees potential $6bn oncology collaboration with Daiichi Sankyocambridgeindependent.co.uk- UM Ventures’ GlycoT Therapeutics grants technology sublicense to Daiichi Sankyothedailyrecord.com
- Apotex Inc. v. Daiichi Sankyo, Inc. (Fed. Cir. 2015)jdsupra.com
- MEsperion to receive $300 million in upfront payments in deal with Daiichi Sankyomarketwatch.com
- AstraZeneca bets $6.9 billion that Daiichi Sankyo therapy will transform cancer treatmentThe Japan Times